U.S. markets closed
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • Dow 30

    34,479.60
    +13.36 (+0.04%)
     
  • Nasdaq

    14,069.42
    +49.09 (+0.35%)
     
  • Russell 2000

    2,335.81
    +24.40 (+1.06%)
     
  • Crude Oil

    70.78
    +0.49 (+0.70%)
     
  • Gold

    1,879.50
    -16.90 (-0.89%)
     
  • Silver

    28.05
    +0.02 (+0.07%)
     
  • EUR/USD

    1.2107
    -0.0071 (-0.58%)
     
  • 10-Yr Bond

    1.4620
    +0.0030 (+0.21%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • USD/JPY

    109.6350
    +0.2870 (+0.26%)
     
  • BTC-USD

    35,728.18
    -1,452.71 (-3.91%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • Nikkei 225

    28,948.73
    -9.83 (-0.03%)
     

Should Value Investors Choose DaVita (DVA) Stock Now?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put DaVita Inc. DVA stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, DaVita has a trailing twelve months PE ratio of 14.73, as you can see in the chart below:



This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 26.22. If we focus on the long-term PE trend, DaVita’s current PE level puts it below its midpoint over (which is 16.6) the past five years. Moreover, the current level stands well below the highs for the stock, suggesting that it can be a solid entry point.



Further, the stock’s PE also compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 24.97. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.


 
We should also point out that DaVita has a forward PE  ratio (price relative to this year’s earnings) of just 14.6, so it is fair to say that a slightly more value-oriented path may be ahead for DaVita stock in the near term too .

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, DaVita has a P/S ratio of about 1.04. This is a bit lower than the S&P 500 average, which comes in at 4.24x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.



If anything, this suggests some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, DaVita currently has a Value Score of A, putting it into the top 20%  of all stocks we cover from this look. This makes DaVita a solid choice for value investors, and some of its other key metrics make this pretty clear too.

For example, the PEG ratio for DaVita is just 0.8, a level that is far lower than the industry average of 2.65. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, DVA is a solid choice on the value front from multiple angles.

What About the Stock Overall?

Though DaVita might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of C and a Momentum Score of D. This gives DVA a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been solid at best. The current quarter has seen six estimates go higher in the past sixty days compared to none lower, while the full year estimate has seen seven up and eight down in the same time period.

This has had a noticeable impact on the consensus estimate though as the current quarter consensus estimate has risen by 16.4% in the past two months, while the full year estimate has increased by 8.9%. You can see the consensus estimate trend and recent price action  for the stock in the chart below:

DaVita Inc. Price and Consensus

DaVita Inc. Price and Consensus
DaVita Inc. Price and Consensus

DaVita Inc. price-consensus-chart | DaVita Inc. Quote

This somewhat favorable trend is why the stock has just a Zacks Rank #2 (Buy) and why we are looking for better performance from the company in the near term.

Bottom Line

DaVita is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 50% of more than 250 industries) instills our confidence. However, over the past two years, the Zacks Medical - Outpatient and Home Healthcare industry has clearly underperformed the broader market, as you can see below:

So, value investors might want to wait for analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot stocks we're targeting >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DaVita Inc. (DVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research